

Use of CryoStor® in Clinical Trials of New Regenerative Medicine Products & Therapies

| Clinical Indication | Administration Route | Reagent Status | Pre-Clinical | Phase I | Phase II | Phase III | Approved | |
|-------------------------------|----------------------|----------------|-------------------------------|---------|----------|-----------|----------|--|
| Disc Repair | N/A | Ancillary | ✓ | ✓ | ✓ | | | |
| Stroke | N/A | Ancillary | ✓ | ✓ | ✓ | | | |
| Malignant Glioma | N/A | Ancillary | ✓ | ✓ | | | | |
| Wound repair | N/A | Ancillary | ✓ | ✓ | ✓ | | | |
| Pediatric Blood Cancers | Intravenous | Excipient | Hospital Practice of Medicine | | | | | |
| Stress Urinary Incontinence | Intraurethral | Excipient | ✓ | ✓ | ✓ | ✓ | | |
| Multiple Sclerosis | Subcutaneous | Excipient | ✓ | | ✓ | | | |
| Amyotrophic Lateral Sclerosis | N/A | Ancillary | ✓ | ✓ | | | | |
| Hematologic Malignancies | Intravenous | Excipient | ✓ | ✓ | ✓ | | | |
| Sickle Cell Disease | Intravenous | Excipient | ✓ | ✓ | ✓ | | | |
| AMD | Sub-retinal | Excipient | ✓ | ✓ | | | | |
| Melanoma | N/A | Ancillary | ✓ | ✓ | | | | |
| Melanoma | N/A | Ancillary | ✓ | ✓ | | | | |
| Hematologic Malignancies | Intravenous | Excipient | ✓ | ✓ | | | | |
| Melanoma | Intratumoral | Excipient | ✓ | ✓ | | | | |
| Ischemic Heart Disease | N/A | Ancillary | ✓ | | | ✓ | | |
| Joint Disease | Intra-articular | Excipient | ✓ | ✓ | ✓ | | | |
| Prostate Cancer | Subcutaneous | Excipient | ✓ | ✓ | | | | |
| AML | Intradermal | Excipient | ✓ | ✓ | ✓ | | | |
| Joint Disease | N/A | Ancillary | ✓ | ✓ | ✓ | ✓ | | |
| CCALD | Intravenous | Excipient | ✓ | | ✓ | ✓ | | |
| PLIF/TLIF | Intravertebral | Excipient | ✓ | ✓ | | | | |
| Disc Repair | Intravertebral | Excipient | ✓ | | | | | |
| Metastatic Melanoma | N/A | Ancillary | ✓ | | ✓ | | | |

| Clinical Indication | Administration Route | Reagent Status | Pre-Clinical | Phase I | Phase II | Phase III | Approved |
|------------------------------|----------------------|----------------|--------------|---------|----------|-----------|----------|
| Prostate Cancer | Intradermal | Excipient | ✓ | ✓ | | | |
| Prostate Cancer | Subcutaneous | Excipient | ✓ | ✓ | ✓ | ✓ | |
| AMI | Intracoronary | Excipient | ✓ | ✓ | ✓ | | |
| Urea Cycle Disorders | N/A | Ancillary | ✓ | ✓ | ✓ | | |
| HIV | N/A | Ancillary | ✓ | ✓ | | | |
| Leukemias | N/A | Ancillary | ✓ | ✓ | ✓ | | |
| Metastatic Melanoma | N/A | Ancillary | ✓ | | ✓ | | |
| Acute Lymphoblastic Leukemia | N/A | Ancillary | ✓ | ✓ | | | |
| Ovarian Cancer | Subcutaneous | Excipient | ✓ | ✓ | ✓ | | |
| Ovarian Cancer | Subcutaneous | Excipient | ✓ | ✓ | ✓ | | |
| Ovarian Cancer | Subcutaneous | Excipient | ✓ | ✓ | ✓ | | |
| Radiation Injury | N/A | Ancillary | ✓ | ✓ | | | |
| Urinary Sphincter Repair | Intramuscular | Excipient | ✓ | ✓ | ✓ | ✓ | |
| Fecal Incontinence | Intramuscular | Excipient | ✓ | ✓ | ✓ | | |
| Ischemic Heart Disease | Intramuscular | Excipient | ✓ | ✓ | ✓ | | |
| Hematologic Malignancies | Intravenous | Excipient | ✓ | ✓ | ✓ | | |
| Metastatic Melanoma | N/A | Ancillary | ✓ | ✓ | ✓ | | |
| beta-thalassemia major | Intravenous | Excipient | ✓ | ✓ | ✓ | | |
| Hematologic Malignancies | N/A | Ancillary | ✓ | ✓ | ✓ | | |
| Treg Production | N/A | Ancillary | ✓ | | | | |
| Organ Rejection | N/A | Ancillary | ✓ | ✓ | | | |
| Non-Hodgkin Lymphoma | N/A | Ancillary | ✓ | ✓ | | | |
| Occlusive Kidney Disease | Intra-arterial | Excipient | ✓ | ✓ | | | |
| Metastatic Cancer | N/A | Ancillary | ✓ | | ✓ | | |
| B Cell Malignancies | N/A | Ancillary | ✓ | ✓ | ✓ | | |
| Metastatic Cancer | N/A | Ancillary | ✓ | ✓ | ✓ | | |
| Malignant Glioma | N/A | Ancillary | ✓ | ✓ | ✓ | | |
| Metastatic Cancer | N/A | Ancillary | ✓ | ✓ | ✓ | | |

| Clinical Indication | Administration Route | Reagent Status | Pre-Clinical | Phase I | Phase II | Phase III | Approved |
|----------------------------|----------------------|----------------|--------------|---------|----------|-----------|----------|
| GI Cancers | N/A | Ancillary | ✓ | | ✓ | | |
| Metastatic Melanoma | N/A | Ancillary | ✓ | | ✓ | | |
| Metastatic Melanoma | N/A | Ancillary | ✓ | | ✓ | | |
| Advanced Melanoma | N/A | Ancillary | ✓ | ✓ | | | |
| HPV Associated Cancers | N/A | Ancillary | ✓ | | ✓ | | |
| Metastatic Ocular Melanoma | N/A | Ancillary | ✓ | | ✓ | | |
| Joint Disease | N/A | Ancillary | ✓ | | | | |
| Crohn's Disease | N/A | Ancillary | ✓ | ✓ | | | |
| Hypoplastic Left Heart | Intracardiac | Excipient | ✓ | ✓ | | | |
| Non-Hodgkin Lymphoma | Intratumoral | Excipient | ✓ | ✓ | | | |
| Ovarian Cancer | N/A | Ancillary | ✓ | ✓ | | | |
| Glioblastoma Multiforme | Intradermal | Excipient | ✓ | ✓ | | | |
| GVHD | Intra-arterial | Excipient | ✓ | | | | |
| Multiple System Atrophy | N/A | Ancillary | ✓ | | | | |
| Hematologic Malignancies | Intravenous | Excipient | ✓ | | | | |
| DC Vaccine Production | N/A | Ancillary | ✓ | | | | |
| Ischemic Stroke | N/A | Ancillary | ✓ | ✓ | ✓ | | |
| AMI | N/A | Ancillary | ✓ | ✓ | ✓ | | |
| Cutaneous Photoaging | N/A | Ancillary | ✓ | ✓ | ✓ | | |

Information deemed accurate as of September 3, 2013, as sourced from www.clinicaltrials.gov and direct customer communication. BioLife Solutions has no obligation to update this information. Please contact support@biolifesolutions.com if you have a question or comment about this information.